ArticleFrontiers in medicine2025
Metabolomic analysis identifies alterations of amino acids in the tears and plasma of patients with dry eye disease with ocular pain.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Identifying the amino acid in tears and plasma and investigating the correlation between amino acid concentrations and the presence of dry eye disease (DED) with ocular pain. Methods: 15 participants in the DED with ocular pain group, 19 in the DED group, and 16 in the control group were enrolled and underwent DED examinations. Evaluation parameters included the Ocular Surface Disease Index score, Numeric Rating Scale score, clinical ocular parameters, as well as measurements from Results: A total of 29 and 36 distinct amino acids were identified in tear fluid and plasma, respectively. The results showed significantly higher levels of methionine (MET) in tear fluid and 1-methyl-L-histidine (1-MEHIS) in plasma in people who developed DED with ocular pain compared to those who did not ( Conclusion: MET in tear fluid and 1-MEHIS in plasma were significantly associated with DED with ocular pain, showing promise as potential biomarkers for DED with ocular pain. Further validation through large-scale studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.